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Abstract The structure of the human A2A adenosine receptor
has been elucidated by X-ray crystallography with a high af-
finity non-xanthine antagonist, ZM241385, bound to it. This
template molecule served as a starting point for the incorpo-
ration of reactive moieties that cause the ligand to covalently
bind to the receptor. In particular, we incorporated a
fluorosulfonyl moiety onto ZM241385, which yielded
LUF7445 (4-((3-((7-amino-2-(furan-2-yl)-[1, 2, 4]triazolo
[1,5-a][1, 3, 5]triazin-5-yl)amino)propyl)carbamoyl)benzene
sulfonyl fluoride). In a radioligand binding assay, LUF7445
acted as a potent antagonist, with an apparent affinity for the
hA2A receptor in the nanomolar range. Its apparent affinity in-
creased with longer incubation time, suggesting an increasing
level of covalent binding over time. An in silico A2A-structure-
based docking model was used to study the binding mode of
LUF7445. This led us to perform site-directed mutagenesis of
the A2A receptor to probe and validate the target lysine amino
acid K153 for covalent binding. Meanwhile, a functional assay
combined with wash-out experiments was set up to investigate
the efficacy of covalent binding of LUF7445. All these experi-
ments led us to conclude LUF7445 is a valuable molecular tool
for further investigating covalent interactions at this receptor. It
may also serve as a prototype for a therapeutic approach in
which a covalent antagonist may be needed to counteract
prolonged and persistent presence of the endogenous ligand
adenosine.
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Introduction
G protein-coupled receptors (GPCRs), all membrane-bound
proteins, represent one of the largest classes of drug targets
and are the anchor point for approx. one third of all marketed
drugs [1]. These proteins are notoriously difficult to handle
outside of their natural membrane context, for instance, in
receptor purification and crystallization. Recently, however,
a combination of technological advances has allowed the
structure elucidation of an increasing number of these impor-
tant drug targets [2–4]. In this context, covalent modification
of the receptor with ligands is emerging as a useful way to
investigate ligand-receptor binding domains in membrane
proteins, also because such covalent ligands, acting as phar-
macological chaperones, tend to stabilize the otherwise fragile
receptor proteins.
Covalent binding of both agonists and antagonists to aden-
osine receptors has known a long history in purinoceptor re-
search. In the 1980s, the adenosine A1 receptor was the pre-
eminent target for such studies [5], eventually leading to the
design of a covalently binding fluorosulfonyl derivative of the
reference antagonist DPCPX, named FSCPX, which appeared
useful also in an in vivo setting [6, 7]. Likewise, the adenosine
A2A receptor has been subjected to such strategies. One
existing example is the para-fluorosulfonyl derivative of
Electronic supplementary material The online version of this article
(doi:10.1007/s11302-016-9549-9) contains supplementary material,
which is available to authorized users.
* Ad P. IJzerman
ijzerman@lacdr.leidenuniv.nl
1 Division of Medicinal Chemistry, Leiden Academic Centre for Drug
Research, Leiden University, P.O. Box 9502, 2300 RA Leiden, the
Netherlands
2 Present address: Jiangsu Key Laboratory of New Drug Research and
Clinical Pharmacy, XuzhouMedical University, 209 Tongshan Road,
Xuzhou, Jiangsu 221004, China
Purinergic Signalling (2017) 13:191–201
DOI 10.1007/s11302-016-9549-9
SCH58261, FSPTP, which was used to investigate the level of
adenosine A2A receptor reserve for agonist activity [8]. The
hA2AAR has relevance in various diseases, and thus, agonists
for increasing blood flow during cardiac nuclear stress tests
[9] and an antagonist for the treatment of Parkinson’s disease
[10] are on the market, and the receptor may also play a role in
cancer-immunotherapy [11]. The hA2AAR has also been one
of the first GPCRs to be crystallized and a wide variety of
crystal structures has been published, including the reported
structures co-crystalized with agonist UK-432097 or antago-
nist ZM241385 [12–14]. Although covalent A2AR antagonists
have been previously synthesized and investigated in terms of
their affinity or potency [8, 15–18], little is known about their
precise binding mode in the receptor and their effects on the
kinetics of interaction.
In this study, we describe our efforts to obtain a covalent
antagonist probe for the hA2AAR, as a logical extension of our
previous research on long residence time antagonists, i.e.,
compounds that dissociate only slowly from the receptor
[19]. We used the antagonist ZM241385 as the starting point
in our design efforts and synthesized a fluorosulfonyl deriva-
tive of it, LUF7445. We then validated this compound to bind
covalently and inhibit the receptor in a number of in vitro
experiments, and provide evidence for its point of attachment
to the receptor.
Methods and materials
Chemicals and reagent
The radioligand [3H] ZM241385 with a specific activity of
50 Ci × mmol−1 was purchased from ARC Inc. (St. Louis,
MO). Unlabelled ZM241385 was a gift from Dr. S.M.
Poucher (Astra Zeneca, Macclesfield, UK). 5 ′-N-
ethylcarboxamidoadenosine (NECA) was purchased from
Sigma-Aldrich (Steinheim, Germany). LUF6632 was synthe-
sized in our lab, as published previously [19]. Adenosine de-
aminase (ADA) was purchased from Boehringer Mannheim
(Mannheim, Germany). Bicinchoninic acid (BCA) and BCA
protein assay reagent were obtained from Pierce Chemical
Company (Rockford, IL, USA). HEK293 cells stably express-
ing the hA2A adenosine receptor (HEK293 hA2AAR) were
kindly provided by Dr. J Wang (Biogen/IDEC, Cambridge,
MA, USA). All other chemicals were of analytical grade and
obtained from standard commercial sources.
Site-directed mutagenesis
Site-directed receptor mutant hA2AAR-K153A
ECL2 was con-
structed by the same procedure reported previously [20]. The
wild type pcDNA3.1-A2AR plasmid DNA with N-terminal
HA and FLAG tags and C-terminal His tag was used as a
template for polymerase chain reaction (PCR) mutagenesis.
Mutant primers for directional PCR product cloning were de-
signed using the online Quickchange primer design program
(Agilent Technologies, Santa Clara, CA), and primers were
obtained from Eurogentec (Maastricht, The Netherlands).
All DNA sequences were verified by Sanger sequencing at
LGTC (Leiden, The Netherlands).
Cell culture, transfection, and membrane preparation
We followed the procedures reported previously [20, 21].
Briefly, human embryonic kidney (HEK) 293 cells were
grown asmonolayers in Dulbecco’s modified Eagle’s medium
supplemented with stable glutamine, 10% newborn calf se-
rum, 50 μg/mL streptomycin, and 50 IU/mL penicillin at
37 °C and 7% CO2 atmosphere. The cells were transfected
with mutant plasmid DNA using the calcium phosphate pre-
cipitation method, followed by a 48-h incubation. And
HEK293 hA2AAR wild type (hA2AAR-WT) cells were grown
as monolayers on 15 cm ø culture plates to 80–90%
confluency in the same medium as the other HEK293 cells
but with the addition of G-418 (500 mg/ml). For both cells
were detached from the plates by scraping them into PBS and
centrifuged to remove PBS buffer. The pellets were resus-
pended in ice-cold Tris-HCl buffer (50 mM, pH 7.4) and then
homogenized. The cell membrane suspensions were centri-
fuged at 100,000×g at 4 °C for 20 min, after which the proce-
dure was repeated one more time. After this, Tris-HCl buffer
was used to resuspend the pellet, and adenosine deaminase was
added to break down endogenous adenosine. Membranes were
stored in 250μL aliquots at −80 °C until further use.Membrane
protein concentrations were measured using the BCA method
[22].
Radioligand displacement assay
Radioligand displacement experiments were performed as fol-
lows. Membrane aliquots containing 10 μg of protein were
incubated in a total volume of 100 μL of assay buffer to adjust
the assay window to approximately 3000 dpm. Nonspecific
binding was determined in the presence of 100 μM NECA
and represented less than 10% of the total binding. Then, to
each tube were added 25 μL cell membrane (10 μg of protein),
25 μL of 2.7 nM radioligand [3H] ZM241383, 25 μL of assay
buffer [25 mM Tris-HCl, pH 7.4 at 25 °C , supplemented with
5 mM MgCl2 and 0.1% (w/v) 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS)], and 25 μL
of the indicated compounds in increasing concentrations in the
same assay buffer. The mixture was incubated at 25 °C for
60 min to reach equilibrium. Incubations were terminated by
rapid vacuum filtration to separate the bound and free
radioligand through 96-well GF/B filter plates using a Perkin
Elmer Filtermate-harvester (PerkinElmer, Groningen,
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Netherlands). Filters were subsequently washed three times
with 2 mL of ice-cold buffer (25 mM Tris-HCl, pH 7.4, sup-
plemented with 5 mM MgCl2). The filter-bound radioactivity
was determined by scintillation spectrometry using a P-E 1450
Microbeta Wallac Trilux scintillation counter (PerkinElmer).
Radioligand competition association assay
The binding kinetics assay to determine the unlabeled ligands
was performed as described previously [21]. Briefly, the asso-
ciation of the radioligand was followed over time in the ab-
sence or presence of a concentration corresponding to the IC50
value of unlabeled ZM241385, LUF6632, and LUF7445. In
practice, to the mixture of equal volumes of radioligand, un-
labeled compound and assay buffer was added a 25 μL mem-
brane aliquot containing 10 μg of protein at each time point
from 0.5 min to 240 min at 25 °C. Incubation was terminated
as described above (Radioligand displacement assay).
Irreversible binding of LUF7445 to both hA2AAR-WT
and hA2AAR-K153A
ECL2 cell membranes
Both hA2AAR-WT and hA2AAR-K153A
ECL2 cell mem-
brane aliquots were treated the same way as described in
the BRadioligand displacement assay^ section to deter-
mine their assay window. Then, 100 μL assay buffer con-
taining either 1% DMSO (as blank control for total bind-
ing and nonspecific binding) or 1 μM ligands (ZM241385
or LUF7445, 400 μM stock in assay buffer) was added to
2-mL Eppendorf tubes containing 100 μL cell membrane
suspension and 200 μL assay buffer and incubated for 1 h
at 25 °C. Subsequently, the mixture was centrifuged at
16,100×g at 4 °C for 5 min to remove the buffer with
the Bfree^ ligands. The membrane pellet was resuspended
in 1 mL assay buffer and spun for 5 min at 16,100×g at
4 °C. After three washing cycles, the cell pellets were
resuspended in 300 μL assay buffer to determine their
radioligand binding activity. Afterwards, all the samples
were transferred to test tubes on ice and 100 μL (2.7 nM)
radioligand [3H] ZM241383 was added, followed by a
0.5-h incubation at 25 °C. The incubation was terminated
by vacuum filtration through a GF/B filter using a Brandel
harvester to separate bound and free radioligand. The fil-
ters were washed three times with ice-cold wash buffer
(25 mM Tris-HCl, pH 7.4 supplemented with 5 mM
MgCl2). After harvesting, 3.5 mL of scintillation liquid
was added and the filter-bound radioactivity was deter-
mined in a Tri-Carb 2900TR liquid scintillation analyzer
(PerkinElmer). Results are expressed as percentage nor-
malized to the maximum specific binding in the control
group (100%).
Cyclic AMP functional assay
The LANCE ultra-cAMP 384 kit (PerkinElmer, Groningen,
Netherlands) was used and all assay components were pre-
pared according to the instructions of the manufacturer.
Briefly, cAMP was generated in the stimulation buffer (N-2-
hydroxyethylpiperazine-N-ethane sulfonic acid (HEPES),
5 mM; 0.1% (w/v) BSA; cilostamide, 50 μM; rolipram,
50 μM; adenosine deaminase (ADA), 0.8 IU mL−1).
HEK293 hA2AAR cells were grown as monolayers to 80–
90% confluency and harvested by centrifugation for 5 min at
200×g. Then, 5000 cells per well were seeded in a 384 well
plate, followed by a 1-h co-incubation with a mixture of
10 nM NECA (prepared in the stimulation buffer) and the
antagonists (LUF7445 or ZM241385) at a concentration rang-
ing from 1 μM to 1 pM. Then, the incubation was terminated
by adding cAMP Tracer solution and anti-cAMP solution.
Measurements of the generated fluorescence intensity were
done on an EnVision Multilabel Reader (PerkinElmer,
Groningen, Netherlands).
Irreversible binding of LUF7445 to HEK293 hA2AAR
cells assessed in cyclic AMP functional assay
All the assay components were prepared as described in the
cAMP functional assay above. HEK293 hA2AAR cells were
grown as monolayers to 80–90% confluency and harvested by
200×g centrifugation for 5 min. Then, cells were pretreated
with ligands at the concentration of their IC80 values (deter-
mined in the cAMP functional assay above), or with stimula-
tion buffer (pH 7.4) for 1 h. Then, the pretreated cells were
centrifuged for 5 min at 300×g to remove the supernatant at
4 °C, after which the cell pellet was washed three times with
3 × 1 mL stimulation buffer, separated by renewed incubation
for 10 min at 25 °C. These washed cells were seeded in a 384
well plate (5000 cells/well) as described in the cAMP func-
tional assay above. Briefly, 10 nM NECA (prepared in the
stimulation buffer) was co-incubated to stimulate cAMP pro-
duction, followed by the termination by cAMPTracer solution
and anti-cAMP solution. Measurements of the generated fluo-
rescence intensity were done on an EnVision Multilabel
Reader (PerkinElmer, Groningen, Netherlands).
Computer modeling
All calculations were performed using the Schrodinger Suite
[23]. The high-resolution crystal structure of the adenosine
A2A receptor co-crystalized with a ZM241385 was used for
the docking studies (PDB:4EIY) [14]. The crystal structure
was prepared using the preparation wizard; protonation states
were assigned using PROPKA [24]. After the protein prepa-
ration, we used the CovDock [25] module to perform covalent
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docking on residue LYS153EL2. Figures were rendered using
PyMol [26].
Data analysis
All the experimental data were analyzed with GraphPad Prism
6.0 software (GraphPad Software Inc., San Diego, CA). The
radioligand displacement curves were fitted to a one-site
binding model. Association data for the radioligand were
fitted using one-phase exponential association. Values for kon
were obtained by converting kobs values using the following
equation: kon = (kobs − koff )/[radioligand], where koff values
were cited from Guo et al. [21] Association and dissociation
rates for unlabelled ligands were calculated by fitting the data
in the competition association model using Bkinetics of com-
petitive binding^ [21, 27].
KA ¼ k1 L½  þ k2
KB ¼ k3 L½  þ k4
S ¼ Sqrt KA−KBð Þ2 þ 4 k1  k3  L I
h i
K F ¼ 0:5 KA þ KB þ Sð Þ
Ks ¼ 0:5 KA þ KB−Sð Þ
Q ¼ Bmax  k1  L K F−KSð Þ−1
Y ¼ Q k4  KF−KSð Þ  KF−1  KS−1 þ k4−KFÞ  KF−1  e−K FX− k4−KSð Þ  KS−1  e−KSX 

where X is the time (min), Y is the specific [3H]-ZM241385
binding (DPM), k1 and k2 are the kon (nM
−1 min−1) and koff
(min−1) of [3H]-ZM241385 and were obtained from Guo et al.
[21], L is the concentration of [3H]-ZM241385 used (nM),
Bmax the total binding (DPM), and I the concentration of un-
labeled ligand (nM). Fixing these parameters allows the fol-
lowing parameters to be calculated: k3, which is the kon value
(nM−1 min−1) of the unlabeled ligand and k4, which is the koff
value (min−1) of the unlabeled ligand. The residence time (RT)
was calculated using RT = 1 / koff [28]. Functional
concentration-effect curves were fitted to a three-parameter
concentration response model. Values are expressed as
mean ± S.E.M. of three independent experiments performed
in duplicate. Statistical analyses were performed using
Student’s unpaired t test (***P < 0.001, **P < 0.01,
*P < 0.05).
Results
Design and synthesis of LUF7445
Over the years, our research group has explored series of
triazolotriazine derivatives based on the reference adeno-
sine A2A antagonist ZM241385, 4-(2-(7-amino-2- (furan-
2 -y l ) - [1 , 2 , 4 ] t r i azo lo [1 ,5 -a ] [1 , 3 ] t r i az in -5 -
ylamino)ethyl)phenol (Fig. 1), to investigate their
structure-activity and structure-kinetics relationships
(SAR and SKR) [22, 29]. We identified LUF6632
(Fig. 1) as a long residence time (RT) compound com-
pared to other derivatives. This compound prompted us
to bring the concept of prolonged receptor occupancy
Fig. 1 Chemical structures of the three hA2A receptor antagonists
examined in this study
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further by aiming for a covalently binding derivative of
ZM241385. Hence, LUF 7445 (Fig. 1), 4-((3-((7-amino-
2-(furan-2-yl)- [1, 2, 4]triazolo[1,5-a] [1, 3]triazin-5-
yl)amino)propyl)carbamoyl)benzene sulfonyl fluoride
was synthesized in three steps from sulfone compound
2-(furan-2-yl)-5-(methylsulfonyl)- [1, 2, 4] triazolo[1,5-
a][1, 3]triazin-7-amine as starting reagent. The reaction
conditions and other reagents used are described in syn-
thetic Scheme 1 of the SI.
Determination of the affinity (Ki) of LUF7445, LUF6632,
and ZM241385 for the A2A receptor
To determine the affinity (Ki) for the A2A receptor
LUF7445, LUF6632 and ZM241385 were tested in a
[3H] ZM241385 displacement experiment (n = 3). All
these compounds concentration-dependently inhibited
specific [3H] ZM241385 binding from human A2A re-
ceptors overexpressed in HEK293 cell membranes
(Fig. 2). LUF6632, ZM241385, and LUF7445 showed
similar affinities in the subnanomolar range (Table 1). It
should be mentioned that the putative covalent nature of
the interaction between receptor and LUF7445 precludes
the determination of equilibrium binding parameters.
Therefore, we expressed LUF7445’s affinity for the
A2A receptor as Bapparent Ki^ (Ki
*).
Time-dependent characterization of affinity for LUF7445,
LUF6632 and ZM241385
We then tested the time dependency of the affinity of the
three compounds. To that end, a [3H] ZM241385 dis-
placement experiment was performed with an incubation
time of both 0.5 and 3 h. As detailed in Table 1, the
affinity of LUF6632 slightly and of LUF7445 strongly
i n c r e a s ed w i t h l onge r i n cuba t i on t ime wh i l e
ZM241385’s affinity did not change. Representative
graphs for this effect are in Fig. 2, in which the curve
representing a concentration-dependent inhibition of spe-
cific [3H] ZM241385 binding was shifted to the left with
time for LUF7445 (Fig. 2a), with little (LUF6632,
Fig. 2b) or no difference (ZM241385, Fig. 2c) for the
other two compounds. Notably, compared to the long res-
idence compound LUF6632, LUF7445 showed a more
pronounced influence with prolonged incubation time,
suggesting an increasing level of covalent binding over
time. The combined data yielded an approx. fivefold shift
in apparent Ki value for LUF7445. The affinities of the
compound for the other adenosine receptor subtypes are
reported in Table S1 of the SI, showing that LUF7445 is
very selective towards A2A receptors.
Kinetic characterization of LUF6632, LUF7445,
and ZM241385 in a competition association binding assay
The Bapparent Ki shift^ of LUF7445 drove us to investigate
the irreversible characteristics of LUF7445 binding by
120
100
80
60
40
20
0
120
100
80
60
40
20
0
Log [LUF7445]
S
p
ec
if
ic
 [
3 H
]Z
M
24
13
85
 b
in
d
in
g
(%
)
LUF7445 3 h
LUF7445 0.5 ha
b
b
0 -12 -11 -10 -9 -8 -7 -6 -5 -4
0 -12 -11 -10 -9 -8 -7 -6 -5 -4
0 -12 -11 -10 -9 -8 -7 -6 -5 -4
Log [LUF6632]
S
p
ec
if
ic
 [
3 H
]Z
M
24
13
85
 b
in
d
in
g
(i
n
 %
)
LUF6632 3 h
LUF6632 0.5 h
Log [ZM241385]
S
p
ec
if
ic
 [
3 H
]Z
M
24
13
85
 b
in
d
in
g
(i
n
 %
)
ZM241385 3 h
ZM241385 0.5 h
120
100
80
60
40
20
0
Fig. 2 Displacement of specific [3H] ZM241385 binding from the
adenosine hA2AAR receptor at 25 °C by LUF7445 (a), LUF6632(b),
and ZM241385(c) during an incubation of 0.5 h (blue curve) and 3 h
(red curve), respectively. Representative graphs are from one
experiment performed in duplicate
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performing kinetic assays to determine its dissociation rate
from the A2A adenosine receptor. In our previous research,
the kon (k1 = 0.24 ± 0.05 × 10
8 M−1 min−1) and koff
(k2 = 0.48 ± 0.03 min
−1) values of [3H]-ZM241385 at 25 °C
have been determined by a traditional association and disso-
ciation assay [21]. Here, we derived the kinetic parameters,
i.e., the kon (k3) and koff (k4) values, for the three unlabeled
ligands from a competition association assay (Fig. 3). Both
LUF6632 (kon = 1.53 ± 0.083 nM
−1 min−1) and ZM241385
(kon = 1.72 ± 0.36 nM
−1 min−1) showed a similar association
rate, which was significantly faster than for LUF7445
(kon = 0.0059 ± 0.00049 nM
−1 min−1). As detailed in
Table 2, LUF6632 displayed a dissociation rate constant of
0.15 ± 0.021 min−1 which equals to a receptor RT of
6.80 ± 0.97 min, being sevenfold longer than ZM241385’s
RT which was 0.96 ± 0.12 min at 25 °C. Figure 3 shows that
LUF7445’s behavior was very different, causing an initial
Bovershoot^ of the competition association curve which over
time progressed to negligible radioligand binding at 240 min.
Analyzing this curve with the (equilibrium), Motulsky and
Mahan model [27] led to a negligible dissociation rate (k-
off = 1.37 ± 0.68 × 10
−11 min−1) and an almost infinite RT
for LUF7445 (values between brackets in Table 2). These data
provided further evidence for a putative irreversible binding
mode between LUF7445 and the hA2A receptor. This data is
qualitatively summarized in a simplified scheme in the SI
(Scheme 2).
Binding mode of LUF7445 in the hA2AAR binding pocket
Although the radioligand binding results above characterized
LUF7445 as an irreversibly binding ZM241385 derivative, it
remained to be tested what the target residue of the reactive
warhead is. We therefore constructed a binding model based
on the reported adenosine A2A X-ray crystal structure (PDB
code: 4EIY) and chemical structure of LUF7445. From the
docking result, the ZM241385 core structure, shown as black
carbon sticks in Fig. 4, is in the same position as ZM241385 in
the A2A crystal structure, participating in H–bond formation
with residues such as His264, Glu169, Phe168, and Asn253.
Due to the flexibility of the three carbon linker, a lysine resi-
due in close proximity of the ligand, K153ECL2, could interact
with the 4-fluorosulfonylbenzoic warhead in LUF7445 to
form a covalent sulfonyl amide.
Lysine K153ECL2 residue is the possible anchor point
for covalent bond formation
To investigate the structural nature of the interaction between
the ligands and receptor, we therefore mutated the potential
target lysine residue to alanine (A2AAR-K153A
ECL2 receptor)
to compare with the wild-type receptor and perform a Bwash-
out^ experiment. Following preincubation with either
LUF7445 or ZM241385, cell membranes overexpressing mu-
tant A2AAR-K153A
ECL2 or wild-type A2AAR were washed
three times to remove the noncovalently bound ligands.
After this repeated washing, cell membranes were incubated
with the radioligand [3H] ZM241385 to assess the remaining
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Fig. 3 Competition association
binding assay with [3H]
ZM241385 in the absence or
presence of indicated compounds
at 25 °C. Representative graphs
are from one experiment
performed in duplicate (see
Table 2 for kinetic parameters)
Table 1 (Apparent) affinities of LUF7445, LUF6632, and ZM241385
for the A2A adenosine receptor
Compound pKi
a
(0.5 h)
pKi
b
(3 h)
LUF7445c 8.27 ± 0.042 8.99 ± 0.008***
LUF6632 9.17 ± 0.007 9.26 ± 0.004*
ZM241385 8.89 ± 0.019 8.91 ± 0.006
Data are expressed as means ± SEM of three separate experiments each
performed in duplicate. *P < 0.05, ***P < 0.001 compared with the pKi
values in displacement experiments during 0.5 h incubation time;
Student’s t test
a Affinity determined from displacement of specific [3 H]ZM241385
binding from the hA2AAR at 25 °C during 0.5 h incubation
b Affinity determined from displacement of specific [3 H]ZM241385
binding from the hA2AAR at 25 °C during 3 h incubation
c For LUF7445, the covalent antagonist, pKi values can only be apparent,
as true equilibrium cannot be reached
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radioligand binding. In the absence of antagonist (labeled B+
vehicle^ in Fig. 5) both the mutant A2AAR-K153A
ECL2 and
the wild-type A2AAR receptor containing membranes had a
similar recovery of radioligand binding, which we normalized
to 100% recovery. LUF7445 caused a significant decrease of
radioligand binding on the A2AAR WT cell membranes with
only 10.4 ± 3.0% recovery of specific binding despite the
extensive washing, while more radioligand binding was
Bsaved^ at the cell membranes overexpressing A2AAR-
K153AECL2 (32.8 ± 0.9% remaining). As a control, both cell
membrane preparations preincubated with ZM241385
showed that ZM241385 was rapidly washed off the mem-
branes, as a full recovery of radioligand bindingwas observed.
Functional characterization of LUF7445 and ZM241385
in cAMP assay
Functional characterization of these compounds in a cAMP
assay on the HEK cells expressing the hA2AAR showed their
antagonist behavior. The cAMP production was stimulated by
the addition of the reference agonist NECA (10 nM). Both
LUF7445 and ZM241385 caused a concentration-dependent
inhibition of NECA’s effect (100% in the absence of antagonist,
see Fig. 6a). The potency of LUF7445 (pIC50 = 8.10 ± 0.044)
was somewhat lower than of ZM241385( pIC50 = 8.71 ± 0.13).
Again, it should be mentioned that LUF7445 precludes a true
equilibrium affinity determination. From Fig. 6a, we deter-
mined the IC80 values of the two compounds, which concen-
trations were then used to pretreat the HEK-A2AAR cells,
followed by three wash steps. Thereafter, we stimulated the
cAMP production in these cells with 10 nM NECA, resulting
in a sustained inhibition of cAMP production in the presence of
LUF7445 (48 ± 1%), while ZM241385 showed no difference
in restoration of cAMPproduction compared to the control cells
in the absence of any indicated compound (Fig. 6b).
Apparently, the cAMP production induced by NECA in the
presence of LUF7445 was inhibited under conditions where a
reference antagonist did not, further validating LUF7445 as a
covalent antagonist forming an irreversible bond with the
hA2AAR.
Discussion
Covalent ligands for GPCRs are emerging as a useful tool for
receptor structure elucidation and the chartering of the ligand-
receptor binding pocket. As an example, the 3D architecture
of the beta2-adrenergic receptor in an active conformation has
been recently determined in the presence of a covalently bind-
ing derivative of noradrenaline [4, 30]. In the current study, we
designed and synthesized a covalent antagonist (LUF7445) to
investigate ligand-receptor interaction in the binding pocket of
the hA2AAR, and compared its behavior to the reference an-
tagonist ZM241,385 and the long residence time ZM-
derivative LUF6632 [19]. All three compounds showed a high
affinity for the hA2AAR.
The rational ligand design came from the reported crystal
structures of the hA2AAR bound to ZM241385, providing a
clear blueprint of ligand binding interactions [13, 14, 31]. A
deep, planar, and narrow cavity holds the aromatic core and
furan ring of ZM241385, while the phenylethylamine substit-
uent is directed to the extracellular region (EL2 and EL3). The
Table 2 The (apparent) associa-
tion and dissociation rate con-
stants of LUF7445, LUF6632,
and ZM241385 determined in
competition association assays
with [3H]-ZM241385 binding to
HEK293-hA2AAR membranes
Compound kon (nM
−1 min−1)a koff (min
−1)a RT (min)
LUF7445b (0.0059 ± 0.00049) (1.37 ± 0.68 × 10−11) (2.86 ± 0.87 × 1011)
LUF6632 1.53 ± 0.083 0.15 ± 0.021 6.80 ± 0.97
ZM241385 1.72 ± 0.36 1.04 ± 0.13 0.96 ± 0.12
a Association (kon) and dissociation (koff) rate constants were determined by competition association assay at
25 °C; all these values were determined by analyzing the data in the mathematical model described by
Motulsky and Mahan [27]
b For LUF7445, no equilibrium is reached between receptors and ligand; hence, the Motulsky/Mahan mathemat-
ical model [27] for the competition association assay is not valid. The values obtained are therefore considered to
provide qualitative insight only, and are in brackets
Fig. 4 Binding model of LUF7445 in the hA2A adenosine receptor-
binding pocket based on the hA2A adenosine receptor crystal structure
(PDB code: 4EIY). The black carbon sticks represent the structure of
LUF7445. The important residues and H–bonds for ligand recognition
are indicated by yellow dashed lines
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architecture of the ligand binding pocket offered us a good
starting point for the structural modification of ZM241385.
Therefore, instead of the 4-hydroxyphenylethylamine side
chain in ZM241,385, the electrophilic fluorosulfonyl group,
chosen to permit a possible nitrogen-to-sulfur bond between
the ligand and a nearby free amino group in the receptor, was
introduced and incorporated in a linker to yield LUF7445.
A first hint of the covalent nature of LUF7445was found in
incubation time-dependent radioligand displacement assays.
A longer incubation time rendered LUF7445 more potent in
displacing the radioligand from the receptor, while this was
not or hardly the case for ZM241384 and LUF6632, respec-
tively. LUF6632 had previously been identified as an antago-
nist with a long residence time (>300 min) at the receptor,
when assessed at 4 °C [19]. The current set of experiments
was performed at 25 °C, making LUF6632 dissociate faster
(RT = 6.8 min, Table 2) from the receptor with no substantial
pKi shift in affinity at the two incubation times. Similar exper-
iments on other GPCRs, such as CB1 cannabinoid receptor
[32, 33] and histamine H2 receptor [34], demonstrated that
the covalent interaction between the ligand and the receptor
resulted in a time-dependent affinity change.
However, it is far from conclusive to identify a presumed
covalent ligand from an affinity shift alone, as pseudo-
irreversible interactions can also occur caused by slow dissoci-
ation rates. From a kinetic perspective, a covalent ligand refers
to a ligand that stays at the receptor for an infinite time period. If
the incubation time is long enough, all receptors will be occu-
pied by the covalent compound, rendering competitive
radioligand binding impossible. In accordance with this, a con-
tinuing decrease of specific radioligand binding was observed
in the kinetic experiments over a 4-h incubation at 25 °C
(Fig. 3). The inadequacy of the Motulsky-Mahan equations
[27] to fit this data is further evidence for the nonequilibrium
features of the binding of LUF7445 to the receptor.
Furthermore, extensive washing did not free the receptors from
LUF7445, as demonstrated by the lack of [3H]ZM241385 bind-
ing (Fig. 5, WT receptor), compared to a full recovery of mem-
branes pretreated with ZM241385. This confirms the washing
steps did remove the reversible ligand from the receptors, and in
return validates the irreversible binding of LUF7445 to the
hA2AAR. Similar findings were obtained on the adenosine A1
receptor and histamine H4 receptor where preincubation of a
covalently binding ligand concentration-dependently decreased
radioligand binding after extensive washing of the cell mem-
brane preparation [7, 35].
Based on the ZM241385 binding mode of the hA2AAR, we
hypothesized that LUF7445 covalently interacts with a lysine
residue, K153ECL2, resulting in a sulfonamide bond formation
(Fig. 4). Hence, the K153AECL2 mutant construct, potentially
preventing the covalent bond from being formed, was made to
perform a similar wash-out experiment as described above.
Since ZM241385 showed a similar affinity for both the
K153AECL2 mutant (pKi = 7.83 ± 0.04) and WT receptors
(pKi = 7.91 ± 0.05) [20], we assumed that the difference in
radioligand binding recovery was not due to a point mutation
within a receptor binding site, which has the potential of al-
tering ligand binding properties. Moreover, in the absence of
either LUF7445 or ZM241385, the apparently same binding
capacity (data not shown) proved that the washing steps had
little influence on the integrity of both WT hA2AAR and mu-
tant A2AAR-K153AECL2. The mutation led to a threefold
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Fig. 5 Involvement of Lys153 in the binding of LUF7445. HEK293 cell
membranes overexpressing wild-type or K153A mutant hA2A AR were
pretreated with buffer (vehicle) or 1 μM of LUF7445 or ZM241385 for
1 h followed by 3 wash cycles. The membranes were then subjected to a
standard [3H] ZM241385 radioligand binding assay to measure
remaining specific [3H] ZM241385 binding. Results were obtained from
three independent experiments performed in duplicate. Data are normal-
ized to 100% of the vehicle group response. Error bars indicate SEM
values.**Significant difference between groups (P < 0.01); Student’s t
test
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increase of binding recovery indicating a substantially de-
creased level of covalent binding to the cell membranes,
resulting from a decreased possibility to form a covalent
bond between the warhead and a target residue. The mu-
tation did not lead to a full recovery of radioligand bind-
ing, however, suggesting that other unidentified residues
may play a similar role. Likewise, Nijmeijer et al. identi-
fied a cysteine amino acid to be the linking residue for the
covalent probe at the histamine H4 receptor mentioned
above [35], and it may be that the very reactive
fluorosulfonyl warhead in LUF7445 also targets other res-
idues such as cysteines [36].
A covalent antagonist will decrease the maximal
agonist-induced effect by a permanent occupancy of the
available receptors, which was indeed demonstrated in the
functional assay. The concentration-effect curves obtained
in the cAMP functional assay showed an antagonistic be-
havior of LUF7445 (Fig. 6a). A much lower stimulation
by AR receptor agonist NECA was observed as the num-
ber of available receptors was most likely reduced by the
irreversible binding of LUF7445 (Fig. 6b). A similar ex-
periment at the adenosine A1 receptor showed that the
irreversible binding by FSCPX decreased the maximal
effect in the agonist dose-response curves [37]. All these
results contributed to our hypothesis that LUF7445 is an
insurmountable antagonist for the hA2AAR indeed, and
that the fluorosulfonyl group present in LUF7445 reacts
with K153ECL2 via a covalent modification.
Besides in clinical trials for Parkinson’s disease, A2A an-
tagonists have risen to prominence as a future add-on to cancer
combination therapy. Under chronic hypoxic conditions with-
in the tumor microenvironment, increased accumulation of
extracellular adenosine around the tumor tissue activates
A2AARs in the vicinity, which promotes peripheral tolerance
by inducing T-cell anergy and the generation of adaptive reg-
ulatory T cells [38]. In contrast, blockade of A2AARs plays a
vital role in retardation of tumor growth, relieving immune
cells from their repressed conditions, reducing the metastasis
of tumors [39], and thus boosting antitumor immunity. As a
consequence potent, A2A receptor antagonists are now being
considered as potential therapeutics in diminishing the rate of
cancer development [40, 41]. The starting point of our design
strategy, ZM241385, has been reported to significantly inhibit
melanoma growth and reinforce the antineoplastic immune
response, when combined with anti-CTLA4mAb [42].
However, in vivo tumor rejection during treatment with
ZM241385 failed to take place most likely because of
ZM241385’s short half-life [11]. In addition, we speculate that
the relatively short receptor residence time of ZM241385 at
physiological temperature is another aspect that allows the
massive amounts of adenosine produced in the tumor environ-
ment to continue to activate the A2AAR. Thus, a covalently
binding antagonist such as LUF7445 may be a better propo-
sition under these conditions.
Conclusion
The structure-based design of LUF7445, an antagonist for the
human A2AAR, is reported in this study. In a number of
in vitro assays, we obtained accumulating evidence for the
covalent nature of the ligand’s interaction with the receptor.
More specifically, LUF7445 appeared to bind covalently to a
lysine residue in the extracellular domain of the receptor
(K153ECL2). Its antagonistic nature was confirmed in a
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Fig. 6 Functional characterization of LUF7445 and ZM241385 on hA2A
AR expressed in HEK293 cells. a Concentration-inhibition curves for
LUF7445 and ZM241385 in a cAMP assay in the presence of 10 nM
NECA (100%). Results were obtained from three independent
experiments performed in triplicate. b Recovery of cAMP production.
Cells were pretreated with a concentration corresponding to the IC80
value (retrieved from Fig. 6a) of the indicated compound, or with buffer
(control) for 1 h. Then, 3 wash cycles were applied, followed by adding
10 nM NECA to stimulate cAMP production. Data are expressed as
means ± SEM of three separate experiments each performed in
duplicate. ***Significant difference between groups (P < 0.001);
Student’s t test
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functional assay, as it blocked hA2AAR-mediated cAMP ac-
cumulation by agonist NECA. The results contribute to a bet-
ter understanding of long-lasting effects caused by ligands
covalently reacting/interacting with GPCRs. In itself,
LUF7445 may be a probe to explore the added value of cova-
lent antagonists for the adenosine A2A receptor in certain dis-
ease states such as cancer immunology, in which high adeno-
sine levels are causative. In the end, rational design of cova-
lent probes may have further value in new technologies such
as activity-based protein profiling with the perspective of im-
aging or structural probing of GPCRs.
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